Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03490760 · ClinicalTrials.gov registry record · Phase 2
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
A Phase 2 study, sponsored by Baptist Health South Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT03490760 is a Phase 2 study that was terminated before completion, run by Baptist Health South Florida. The registered enrollment target is 9 participants.
The verdict
NCT03490760, a Phase 2 study, was terminated before completion, sponsored by Baptist Health South Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.
Interventions
- RADIATION Radiation Therapy
- DRUG Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2018-11-09 |
| Est. Completion | 2020-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03490760
The ClinicalTrials.gov registry entry for NCT03490760 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT03490760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03490760 about?
NCT03490760 is a clinical study titled "Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas". This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.
What is the current status of trial NCT03490760?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2018-11-09. Estimated completion is 2020-07-09.
What interventions are being tested in trial NCT03490760?
The interventions under investigation include: Radiation Therapy (RADIATION), Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03490760?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.